Novartis selects Quantum for eczema drug

Published on .

Novartis Pharmaceuticals Corp., East Hanover, N.J., tapped CommonHealth's Quantum Group, Parsippany, N.J., to handle consumer promotions for a still-in-development eczema drug known as SDZ ASM 981. Another CommonHealth arm, Noesis Healthcare Interactions, will handle promotions aimed at healthcare professionals. The drug is billed as a revolution in the treatment of eczema, a common skin disorder.

Copyright November 2000, Crain Communications Inc.

In this article:
Most Popular